Evidence map›Paper›PMID 40008147›Full record

Trial reportFrontiers in public health2025

Universal capillary screening for chronic autoimmune, metabolic and cardiovascular diseases: feasibility and acceptability of the UNISCREEN study.

Sara Angiulli, Aurora Merolla, Elisa Borgonovo, Rebecca De Lorenzo, Serena Spadoni, Barbara Fontana, Giuseppina Manganaro, Elena Rela, Alberto Bongiovanni, Rita Peracino and 8 more

Registry-linked trialAbstract readClinical Trial
In one paragraph

Trial report in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05841719 (General Population Universal Capillary Screening for Chronic Autoimmune, Metabolic and Cardiovascular Diseases), which is not on this map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05841719 nacompletednot on this map

General Population Universal Capillary Screening for Chronic Autoimmune, Metabolic and Cardiovascular Diseases (UNISCREEN): Feasibility and Acceptability Pilot Study.

TypeinterventionalSponsorEmanuele BosiRan2023 to 2024Enrolled1,535ConditionsCardiovascular Risk Factors, Autoimmune DiseasesArmsScreening test
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Sara AngiulliVita-Salute San Raffaele University, Milan, Italy.
Aurora MerollaVita-Salute San Raffaele University, Milan, Italy.
Elisa BorgonovoVita-Salute San Raffaele University, Milan, Italy.
Rebecca De LorenzoVita-Salute San Raffaele University, Milan, Italy.
Serena SpadoniDiabetes Research Institute, IRCCS San Raffaele Hospital, Milan, Italy.
Barbara FontanaDiabetes Research Institute, IRCCS San Raffaele Hospital, Milan, Italy.
Giuseppina ManganaroVita-Salute San Raffaele University, Milan, Italy.
Elena RelaVita-Salute San Raffaele University, Milan, Italy.
Alberto BongiovanniVita-Salute San Raffaele University, Milan, Italy.
Rita PeracinoVita-Salute San Raffaele University, Milan, Italy.
Chiara BellinoVita-Salute San Raffaele University, Milan, Italy.
Giulia PataVita-Salute San Raffaele University, Milan, Italy.
Eleonora BianconiVita-Salute San Raffaele University, Milan, Italy.
Sabina MartinenghiVita-Salute San Raffaele University, Milan, Italy.
Francesca UliviFondazione Italiana Diabete (FID), Milan, Italy.
Cristina RenziVita-Salute San Raffaele University, Milan, Italy.
Emanuele BosiVita-Salute San Raffaele University, Milan, Italy.
UNISCREEN Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: UNISCREEN is a general population study aiming at evaluating feasibility and acceptability of universal screening for chronic autoimmune (type 1 diabetes and celiac disease) and metabolic/cardiovascular diseases (dysglycemia, type 2 diabetes, dyslipidemia, hypertension) across all age groups using capillary blood sampling by fingerprick to measure disease risk markers. Methods: UNISCREEN was conducted in the Cantalupo fraction, Cerro Maggiore, Milan, Italy, counting 3,061 inhabitants between 1 and 100 years of age. Participation was voluntary, following a public call. Participants were invited to respond to feasibility and acceptability questionnaires immediately before and after the screening procedures, which included the following: capillary blood drawing for immediate measurement of metabolic parameters (glucose, glycated hemoglobin, total-, HDL- and calculated LDL-cholesterol, triglycerides) and late autoantibody assays; blood pressure measurement; brief consultation with a physician providing feed-back on immediate results and health recommendations. The study was registered as ClinicalTrials.gov NCT05841719. Results: The study included 1,535 participants (50.1% of local population). A single fingerprick was sufficient for all measurements in 47.1% of cases, while up to two were necessary in 86.9% of cases. Complete glucose and lipid panels were obtained in 1382 participants (90.0%). Sufficient serum for late autoantibody testing was obtained in 99.7% of participants. The questionnaires showed overall satisfaction, with over 90% of participants considering capillary sampling simple and practical, and preferring it to venous sampling. Before screening, 24.0% adults and 31.7% children's parents were worried about the possibility of being diagnosed or identified as being at risk; worries decreased to 21.3 and 23.4%, respectively, after medical consultation. The immediacy of some result communication possibly contributed to reducing the anticipatory anxiety. Conclusion: The UNISCREEN study shows that universal screening for chronic autoimmune, metabolic and cardiovascular diseases in the general population using capillary blood testing is feasible and acceptable.

Indexed as

Autoimmune DiseasesCardiovascular DiseasesMass ScreeningMetabolic DiseasesAdolescentAdultAgedAged, 80 and overChildChild, PreschoolDiabetes Mellitus, Type 1Feasibility StudiesFemaleHumansInfantItalycapillary bloodcardiovascular diseasesceliac diseasedyslipidemiafeasibility and acceptabilitypopulation screeningtype 1 diabetestype 2 diabetes

Identifiers

PMID40008147
PMCPMC11850345

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.